Clariant (CLN) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
21 Aug, 2026Executive summary
Q2 2025 sales were CHF 968 million, flat in local currency but down 8% in CHF due to FX; H1 2025 sales reached CHF 1.981 billion, up 1% in local currency but down 4% in CHF, with growth in Catalysts and Adsorbents & Additives offsetting a slight decline in Care Chemicals.
Q2 2025 EBITDA before exceptionals rose 3% to CHF 169 million (17.5% margin, up 200 bps YoY), driven by Catalysts and Adsorbents & Additives; H1 EBITDA before exceptionals was CHF 359 million (18.1% margin, up 130 bps YoY).
Net income for H1 2025 dropped to CHF 44 million from CHF 176 million prior year, mainly due to CHF 60 million restructuring charges and CHF 30 million impairments.
Free cash flow conversion improved to 37% (LTM), with H1 operating cash flow at CHF 116 million.
CHF 80 million savings program underway, with CHF 12 million achieved in H1 2025; significant restructuring, impairment, and exceptional expenses recorded.
Financial highlights
Q2 2025 EBITDA before exceptionals increased 3% YoY to CHF 169 million (17.5% margin, up 200 bps); H1 EBITDA before exceptionals CHF 359 million (18.1% margin, up 130 bps).
Reported EBITDA for H1 2025 was CHF 291 million (-14% YoY) due to restructuring charges; net income CHF 44 million.
Gross margin for H1 2025 was 29.6%, down from 30.7% prior year.
Net debt increased to CHF 1.596 billion, with net debt/EBITDA at 2.6x (2.4x before exceptionals).
Basic EPS fell to CHF 0.08 from CHF 0.48 year-over-year.
Outlook and guidance
2025 sales growth guidance revised to 1–3% in local currency due to weak industrial production and market uncertainty.
EBITDA margin before exceptionals confirmed at 17–18% for 2025; reported margin expected at 15.0–15.5%.
Medium-term targets: 4–6% CAGR sales growth, 19–21% EBITDA margin, and ~40% FCF conversion by 2027.
Capex targeted at CHF 200 million for 2025; CHF 75 million restructuring charges expected.
Ongoing macroeconomic uncertainties and trade tensions expected to weigh on demand and volumes.
Latest events from Clariant
- EBITDA margin rose to 18.2% in Q2 2026, with net income and cash flow both improving.CLN
Q2 2026 - Sales and margins declined in Q1 2026, but cash flow and cost savings improved amid global challenges.CLN
Q1 2026 - EBITDA margin rose to 17.8% in 2025, with flat sales and strong free cash flow conversion.CLN
Q4 2025 - EBITDA margin before exceptional items rose to 17.9% in Q3 2025 despite lower sales.CLN
Q3 2025 - Targets 4–6% sales growth, 19–21% margins, and upgraded ESG goals by 2027.CLN
CMD 2024 - Q3 2024 sales fell, but resilient margins support 16% EBITDA margin guidance for 2024.CLN
Q3 2024 - EBITDA margin guidance raised to 16% as cost savings and portfolio actions drive resilience.CLN
Q2 2024 - Q1 2025 delivered higher margins and resilient growth, with cautious guidance amid global uncertainty.CLN
Q1 2025 - 2024 delivered higher margins and cash flow; 2025 targets further margin gains and cost savings.CLN
Q4 2024